The Institute for Quality and Efficiency in Healthcare (IQWiG) (German: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesenis) is a German agency responsible for assessing the quality and efficiency of medical treatments, including drugs, non-drug interventions (e.g. surgical procedures), diagnostic and screening methods, and treatment and disease management. IQWiG also supplies health information to patients and the general community. The organization is independent of the pharmaceuticals industry, contracted solely by the Federal Ministry of Health and the Joint Federal Committee. IQWiG was founded in 2004 under the directorship of Dr Peter Sawicki, who was in September 2010 replaced by Dr Jürgen Windeler. Its deputy director is Dr Stefan Lange. IQWiG is divided into the following departments, which publish reports: General health information, written in plain language, is additionally produced by a Health Information department. These departments are also supported by Administration and Communication departments.
The antiviral drug tenofovir alafenamide (TAF) has been used since 2015 in different combinations for the treatment of HIV and has already been subject to 3 early benefit assessments for this therapeutic indication. It has ...
0
0
Psoriasis is an incurable chronic disease with a hereditary component, in which the body's immune system attacks parts of the skin. This leads to scaly red patches, which can be very itchy. About two million people in Germany ...
0
0
In non-small cell lung cancer (NSCLC) that has already formed metastases, the suitable treatment depends, among other factors, on the genes that are activated in the tumour cells and whether mutations have occurred that make ...
0
0
Repeated acute inflammation and enlargement of the palatine tonsils (in short: tonsils) especially affect children and adolescents. In Germany, no uniform indication for surgical removal of the tonsils has so far been established, ...
0
0
For the first time since the corresponding law became effective in 2012, the German Institute for Quality and Efficiency in Health Care (IQWiG) has published an assessment of the potential of a new treatment method according ...
1
0
The German Institute for Quality and Efficiency in Health Care (IQWiG) has completed 8 assessments of the benefit and potential of new treatment methods with high-risk class medical devices. Besides targeted lung denervation ...
0
0
Palbociclib (trade name: Ibrance) has been approved since November 2016 for the treatment of women with advanced hormone receptor-positive breast cancer who are not eligible for chemotherapy, radiotherapy or further surgery. ...
0
0
The German Institute for Quality and Efficiency in Health Care (IQWiG) assessed the benefit of newborn screening for severe combined immunodeficiency (SCID). Without treatment most young children with SCID die within 1 to ...
0
0
Whether the measurement of the myocardial fractional flow reserve (FFR) in patients with coronary heart disease (CHD) can contribute to an appropriate decision for or against the widening of coronary arteries was the subject ...
0
0
Since August 2016 crizotinib (trade name: Xalkori) has also been available for adults with advanced non-small cell lung cancer (NSCLC) in whom the structure of the enzyme "proto-oncogene tyrosine-protein kinase" (ROS1) is ...
0
0
